본문바로가기
Q
U
I
C
K

Science & Technology

SK bioscience provides various vaccine platforms based on the company's R&D and manufacturing capabilities.

Production

Established in 2012, L HOUSE is the largest cell culture vaccine plant in South Korea.
L HOUSE is capable of mass manufacturing
as the Korea's largest vaccine plant equipped with specialized technology.

Capabilities

SK bioscience manufactures products under its technological expertise and cutting-edge facilities.

Capabilities images
Pioneer in successful adaptation of ‘single-use system’ for vaccines on commercial scale
  • 1. Flexibility in using single-use system
    • Faster execution for process development & scale-up
    • Cost effectiveness based on quick turnaround time, easy validation, without any cleaning process.
  • 2. Diverse platforms
    • Diverse vaccine production in one suite
    • Flexible & rapid supply of clinical materials and commercial products
  • 3. Future expansion
    • Rapid expansion for capacity increase
‘Multi-modular system’ for diverse vaccine types
Fermentation
  • E coli/yeast
  • Polysaccharide
Protein conjugate
  • DT/CRM197/TT
Cell culture
  • Suspension
  • Adherent
  • Microcarrier
Recombination
  • Commercial
    • SKYCellflu
    • SKYZoster
    • SKYVaricella
    • SKYCovione
  • In-house R&D
    • HPV
    • Oral Rota
    • Next PCV
    • COVID 19
    • Sarbecovirus
  • Partnership R&D
    • TCV
    • NRRV
    • COVID 19
    • Sarbecovirus